TBPHCongressional Stock Trades
Theravance Biopharma, Inc.
Pharmaceutical Preparations
Congressional stock trades in Theravance Biopharma, Inc. (TBPH) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
1
Politicians Trading
1
Last Traded
Mar 24, 2025
Price History
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
1 members of Congress have disclosed 1 trades in Theravance Biopharma, Inc. (TBPH). Most active: George Whitesides (1).
Across all disclosures, members of Congress reported 0 purchases and 1 sales of Theravance Biopharma, Inc. (TBPH). The most recent trade was on Mar 24, 2025.
George Whitesides disclosed selling Theravance Biopharma, Inc. (TBPH) on Mar 24, 2025, valued at $15,001 - $50,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.